Biotech catalysts: the full taxonomy

A 'catalyst' is any scheduled or unscheduled event that can sharply re-rate a biotech. They cluster into a few categories — here's the landscape.

FDA / regulatory

• PDUFA date — the FDA's decision deadline on a drug application (approval, CRL, or delay).
• Advisory Committee (AdComm) — outside experts vote a recommendation ahead of a decision; non-binding but market-moving.
• NDA/BLA submission & acceptance — filing the application, and the FDA accepting it for review with a PDUFA date.
• sNDA / label expansion — seeking approval for a new indication of an already-approved drug.
• Designations — Fast Track, Breakthrough Therapy, Orphan Drug, Priority Review, Accelerated Approval; each can speed timelines or signal FDA interest.
• Complete Response Letter (CRL) — the FDA declines to approve and lists deficiencies (negative).
• Clinical hold — the FDA pauses a trial over safety concerns (negative).

Clinical trial events

• Topline readouts — the headline results of a Phase 1/2/3 trial; Phase 3 carries the most weight.
• Interim analyses / DSMB decisions — a monitoring board may stop a trial early for efficacy, futility, or safety.
• Trial initiation & enrollment completion — progress milestones that anchor timing.

Scientific conferences

• Detailed data presentations at major medical meetings (e.g. ASCO in oncology, ASH in hematology, AHA/ACC in cardiology) — often reveal more than the topline.

Corporate & commercial

• Partnerships & licensing deals — upfront cash and validation, often non-dilutive.
• M&A — acquisition of, or by, the company.
• Drug launch & sales — first commercial sales and the quarterly revenue ramp.
• Financings — PIPEs and offerings bring cash in, but are usually dilutive.

International & other

• EMA / CHMP opinions and approvals outside the US.
• Reimbursement / pricing decisions and patent rulings.

How we track them

We currently ingest trial readouts from ClinicalTrials.gov, with PDUFA/AdComm extraction from SEC filings on the roadmap. Every catalyst is scored against price, dilution, short interest and analyst data — see the other guides.